PMID- 37448121
OWN - NLM
STAT- MEDLINE
DCOM- 20240117
LR  - 20240118
IS  - 2005-9256 (Electronic)
IS  - 1598-2998 (Print)
IS  - 1598-2998 (Linking)
VI  - 56
IP  - 1
DP  - 2024 Jan
TI  - First-Line Alectinib vs. Brigatinib in Advanced Non-Small Cell Lung Cancer with 
      ALK Rearrangement: Real-World Data.
PG  - 61-69
LID - 10.4143/crt.2023.461 [doi]
AB  - PURPOSE: Alectinib and brigatinib are second-generation anaplastic lymphoma 
      receptor tyrosine kinases (ALKs) that are widely used as first-line therapy for 
      treating ALK-positive advanced non-small cell lung cancer (NSCLC). Given the lack 
      of a head-to-head comparison of these drugs as first-line therapies, this 
      retrospective observational study aimed to compare the real-world efficacy and 
      safety of alectinib and brigatinib. MATERIALS AND METHODS: Patients who received 
      alectinib or brigatinib as the first-line treatment for ALK-positive advanced 
      NSCLC were evaluated for clinical outcomes of objective response rate (ORR), 
      intracranial ORR, time to next treatment (TTNT), progression-free survival (PFS), 
      overall survival (OS), and safety profiles. RESULTS: Of 208 patients who received 
      either alectinib or brigatinib as a first-line treatment, 176 received alectinib 
      and 32 received brigatinib. At the data cutoff point, the median follow-up 
      duration was 16.5 months (95% confidence interval [CI], 14.7 to 18.3) in the 
      brigatinib group and 27.5 months (95% CI, 24.6 to 30.4) in the alectinib group. 
      The ORR was 92.5% with alectinib and 93.8% for brigatinib. The intracranial ORR 
      rates were 92.7% (38/41) and 100% (10/10), respectively. The rate of PFS at 12 
      months was comparable between the alectinib group and the brigatinib groups 
      (84.4% vs. 84.1%, p=0.64), and the median TTNT, PFS, and OS were not reached in 
      either group. Treatment-related adverse events were usually mild, and treatment 
      discontinuation due to adverse events was rare (alectinib 4.5% vs. brigatinib 
      6.25%). CONCLUSION: Alectinib and brigatinib had similar clinical benefits when 
      used as the first-line treatment of NSCLC patients with ALK rearrangement in the 
      real world.
FAU - Jeon, Youngkyung
AU  - Jeon Y
AD  - Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, 
      Sungkyunkwan University School of Medicine, Seoul, Korea.
FAU - Park, Sehhoon
AU  - Park S
AD  - Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, 
      Sungkyunkwan University School of Medicine, Seoul, Korea.
FAU - Jung, Hyun Ae
AU  - Jung HA
AD  - Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, 
      Sungkyunkwan University School of Medicine, Seoul, Korea.
FAU - Sun, Jong-Mu
AU  - Sun JM
AD  - Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, 
      Sungkyunkwan University School of Medicine, Seoul, Korea.
FAU - Lee, Se-Hoon
AU  - Lee SH
AD  - Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, 
      Sungkyunkwan University School of Medicine, Seoul, Korea.
FAU - Ahn, Jin Seok
AU  - Ahn JS
AD  - Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, 
      Sungkyunkwan University School of Medicine, Seoul, Korea.
FAU - Ahn, Myung-Ju
AU  - Ahn MJ
AD  - Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, 
      Sungkyunkwan University School of Medicine, Seoul, Korea.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20230714
PL  - Korea (South)
TA  - Cancer Res Treat
JT  - Cancer research and treatment
JID - 101155137
RN  - LIJ4CT1Z3Y (alectinib)
RN  - HYW8DB273J (brigatinib)
RN  - 0 (Piperidines)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Carbazoles)
RN  - 0 (Organophosphorus Compounds)
RN  - 0 (Pyrimidines)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics
MH  - *Lung Neoplasms/drug therapy/genetics
MH  - Piperidines/adverse effects
MH  - Protein Kinase Inhibitors/adverse effects
MH  - *Carbazoles
MH  - *Organophosphorus Compounds
MH  - *Pyrimidines
PMC - PMC10789949
OTO - NOTNLM
OT  - Alectinib
OT  - Anaplastic lymphoma kinase
OT  - Brigatinib
OT  - Non-small-cell lung carcinoma
COIS- Conflicts of Interest Conflict of interest relevant to this article was not 
      reported.
EDAT- 2023/07/14 13:07
MHDA- 2024/01/17 06:42
PMCR- 2024/01/01
CRDT- 2023/07/14 01:44
PHST- 2023/03/14 00:00 [received]
PHST- 2023/07/12 00:00 [accepted]
PHST- 2024/01/17 06:42 [medline]
PHST- 2023/07/14 13:07 [pubmed]
PHST- 2023/07/14 01:44 [entrez]
PHST- 2024/01/01 00:00 [pmc-release]
AID - crt.2023.461 [pii]
AID - crt-2023-461 [pii]
AID - 10.4143/crt.2023.461 [doi]
PST - ppublish
SO  - Cancer Res Treat. 2024 Jan;56(1):61-69. doi: 10.4143/crt.2023.461. Epub 2023 Jul 
      14.